Statistics from Altmetric.com
Cutaneous adverse effects are very common with anticancer drug therapy. Imatinib mesylate is a very common drug used for the treatment of chronic myeloid leukaemia (CML) and other malignancies. About 9.5%–69% of the patients treated with imatinib have experienced at least one cutaneous side effect.1 There are only few case reports of imatinib-induced nail pigmentation as the only mucocutaneous side effects.2 3 Here, we report a young female patient developing nail pigmentation involving all 20 nails after the treatment with imatinib for CML.
A 24-year-old woman with fever, weakness, dizziness and pallor for 2–3 weeks came to medicine department. The routine investigation revealed low haemoglobin with increased leucocytes and metamyelocyte, promyelocytes in peripheral smear. The patient was …
Contributors Contribution of the corresponding author is in designing the work, analysing and interpreting the data, drafting the work, finalising the version to be published and agreeing to be accountable for all aspect of the work. Contribution of coauthor is in designing the study, interpretation of data, drafting and revising the content and approving the final version to be submitted.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.